Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

被引：0
作者：
María José Méndez-Vidal
Áurea Molina
Urbano Anido
Isabel Chirivella
Olatz Etxaniz
Eva Fernández-Parra
Marta Guix
Carolina Hernández
Julio Lambea
Álvaro Montesa
Álvaro Pinto
Silverio Ros
Enrique Gallardo
机构：
[1] Maimonides Institute of Biomedical Research (IMIBIC),Oncology Department
[2] Reina Sofia Hospital,Oncology Department
[3] Complejo Hospitalario Universitario A Coruña,Oncology Department
[4] Complejo Hospitalario Universitario de Santiago,Oncology Department
[5] Hospital Clínico Universitario de Valencia,Oncology Department
[6] Hospital Universitari Germans Trias i Pujol,Oncology Department
[7] Hospital Nuestra Señora del Valme,Oncology Department
[8] Hospital del Mar,Medical Oncology Department
[9] Hospital Universitario Nuestra Señora de Candelaria,Medical Oncology Department
[10] Hospital Clínico Universitario Lozano Blesa,Medical Oncology Department
[11] Hospital Regional de Málaga,Medical Oncology Department
[12] Hospital la Paz,Oncology Department
[13] Hospital Universitario Virgen de la Arrixaca,Oncology Department
[14] Parc Taulí Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí I3PT. Universitat Autònoma de Barcelona,undefined
来源：
BMC Pharmacology and Toxicology | / 19卷
关键词：
Antineoplastic agents; Carcinoma, renal cell; Kidney neoplasms; Protein kinase inhibitors; Quality of life; Pazopanib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 345 条
  • [1] Torre LA(2015)Global cancer statistics, 2012 CA Cancer J Clin 65 87-108
  • [2] Bray F(2000)Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors Cancer 89 604-614
  • [3] Siegel RL(2010)Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma J Urol 183 1309-1315
  • [4] Ferlay J(2003)Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol Clin North Am 30 843-852
  • [5] Lortet-Tieulent J(2017)Renal cell carcinoma Nat Rev Dis Primers 3 17009-116
  • [6] Jemal A(2016)An integrated metabolic atlas of clear cell renal cell carcinoma Cancer Cell 29 104-383
  • [7] Moch H(2010)Differential diagnosis of renal tumours with clear cell histology Pathology 42 374-13
  • [8] Gasser T(2011)Tumor biology and prognostic factors in renal cell carcinoma Oncologist 16 4-53
  • [9] Amin MB(2016)First-line antiangiogenics for metastatic renal cell carcinoma: a systematic review and network meta-analysis Crit Rev Oncol Hematol 107 44-188
  • [10] Torhorst J(2017)Systemic therapy in metastatic renal cell carcinoma World J Urol 35 179-1068
12345678910